Samsung Medical Center
Seoul, South Korea
Location status: Recruiting
NCT Number: NCT07452432
This is a single-center, prospective, non-interventional observational cohort study designed to establish a structured recurrence monitoring platform in Korean patients with high-grade non-metastatic upper tract urothelial carcinoma (UTUC).
Eligible adult patients scheduled to receive neoadjuvant chemotherapy followed by radical nephroureterectomy will undergo circulating tumor DNA (ctDNA) sampling prior to chemotherapy initiation and once between 1-6 months after surgery.
Clinical, imaging, pathological, and longitudinal follow-up data will be prospectively collected to enable long-term monitoring of recurrence and survival outcomes.
The primary objective is to establish a prospective cohort integrating clinical and molecular data to support future translational research and recurrence prediction modeling in UTUC.
Interested in participating?
Request Info19 year and older
All sexes
Observational
Seoul, South Korea
Location status: Recruiting
Upper tract urothelial carcinoma (UTUC) is an aggressive malignancy with a high rate of recurrence and metastatic progression following definitive surgery. Although circulating tumor DNA (ctDNA) has shown promise for minimal residual disease detection and early recurrence monitoring in urothelial carcinoma, prospective data in UTUC, particularly in Asian populations, remain limited.
This single-center, prospective, non-interventional observational cohort study aims to establish a structured recurrence monitoring cohort in Korean patients with high-grade non-metastatic UTUC. Adult patients with clinical stage cT2-T4, cN0-1, M0 disease who are planned for neoadjuvant chemotherapy followed by radical nephroureterectomy will be enrolled after providing written informed consent.
ctDNA blood samples will be collected prior to initiation of neoadjuvant chemotherapy and once between 1-6 months following surgery. All treatment decisions, imaging evaluations, and follow-up assessments will be conducted according to standard clinical practice without protocol-mandated interventions.
Demographic, clinical, imaging, pathological, treatment, and longitudinal outcome data will be prospectively collected for up to five years. The study is designed as a cohort-establishment platform and does not test a predefined interventional hypothesis. The accumulated data will serve as a foundation for future recurrence prediction modeling and precision oncology research in UTUC.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Histologically confirmed high-grade upper tract urothelial carcinoma (renal pelvis and/or ureter)
Clinical stage cT2-T4, cN0-1, M0
Planned neoadjuvant chemotherapy followed by radical nephroureterectomy
ECOG performance status 0-1
Adequate hematologic, hepatic, and renal function
Ability to provide written informed consent
Exclusion criteria
Contraindication to cisplatin-based chemotherapy
Uncontrolled infection or severe comorbid medical condition
Pregnancy or breastfeeding
Any condition that, in the investigator's judgment, makes participation inappropriate
Peripheral blood samples (20-30 mL) will be collected prior to neoadjuvant chemotherapy initiation and once between 1-6 months after surgery for circulating tumor DNA (ctDNA) analysis. No investigational drug or device is administered. All oncologic treatments are conducted according to standard clinical practice.
Time frame: From date of radical nephroureterectomy to first documented recurrence or last follow-up (up to 5 years)
Recurrence is defined as radiographic and/or pathologic evidence of local recurrence, regional nodal recurrence, distant metastasis, or intravesical recurrence documented during routine follow-up.
Time frame: From date of surgery to death from any cause or last follow-up (up to 5 years)
Time frame: From date of surgery to death due to UTUC or last follow-up (up to 5 years)
Time frame: Baseline (pre-NAC) and postoperative 1-6 months
Contact information is provided by the study sponsor or research team.
Samsung Medical Center
Other
Prospective Establishment of a Recurrence Monitoring Cohort in Korean Patients With Upper Tract Urothelial Carcinoma
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07518043
Carcinoma, Carcinoma, Transitional Cell
Fuzhou, China
View Trial DetailsNCT07277413
Adenocarcinoma Of Esophagus, Adenocarcinoma of Esophagus
Santa Rosa, California, United States
View Trial DetailsNCT07614594
Bladder Cancer (BC), Carcinoma
Zhengzhou, Henan, China
View Trial DetailsNCT07673016
Bladder Cancer, Carcinoma
Oceanside, California, United States
View Trial Details